# IgAN FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/igan

> 1 upcoming FDA catalyst in IgAN: JADE-001 (JBIO) on Q2 2027 (interim data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for IgAN?

1 upcoming FDA catalyst in IgAN: JADE-001 (JBIO) on Q2 2027 (interim data readout). Press release filed with the SEC (EX-99): "JADE101 Phase 2 clinical trial in IgA nephropathy (JUNIPER) ongoing; interim data expected in the second quarter of 2027" [Calendar and source filings](https://sec-api.dev/indications/igan)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-459287, https://www.sec.gov/Archives/edgar/data/1798749/000119312526459287/d157312dex991.htm (retrieved 2026-11-14). Last confirmed 2026-11-13. Cite: https://sec-api.dev/indications/igan#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 30, 2025 | [Felzartamab trial start](https://sec-api.dev/pdufa/felzartamab) | BIIB | IgAN | completed | "During the first quarter of 2025 we accrued a milestone payment due to MorphoSys of $35.0 million upon the first patient dosed in a Phase 3 clinical trial of felzartamab for the treatment of AMR, which was recorded within acquired in-process research and development, upfront and milestone expense in our condensed consolidated statements of income for the six months ended June 30, 2025, and subsequently paid in April 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/875045/000087504525000033/biib-20250630.htm)) |
| September 30, 2025 | [Felzartamab trial start](https://sec-api.dev/pdufa/felzartamab) | BIIB | IgAN | completed | "During the first quarter of 2025 we accrued a milestone payment due to MorphoSys of $35.0 million upon the first patient dosed in a Phase 3 clinical trial of felzartamab for the treatment of AMR, which was recorded within acquired in-process research and development, upfront and milestone expense in our condensed consolidated statements of income for the nine months ended September 30, 2025, and paid in April 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/875045/000087504525000049/biib-20250930.htm)) |
| Q2 2027 | [JADE-001 interim data readout](https://sec-api.dev/pdufa/jade101) | JBIO | IgAN | scheduled | "JADE101 Phase 2 clinical trial in IgA nephropathy (JUNIPER) ongoing; interim data expected in the second quarter of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1798749/000119312526459287/d157312dex991.htm)) |

## Drugs

- [Felzartamab](https://sec-api.dev/pdufa/felzartamab) (BIIB)
- [JADE-001](https://sec-api.dev/pdufa/jade101) (JBIO)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/igan.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IgAN FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/igan

```bibtex
@misc{secapidev_indications_igan_20261116,
  title        = {IgAN FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/igan}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_igan_20261116","title":"IgAN FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/igan","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
